View ValuationICON 将来の成長Future 基準チェック /26ICON利益と収益がそれぞれ年間15.5%と1.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.9% 20.2%なると予測されています。主要情報15.5%収益成長率20.23%EPS成長率Life Sciences 収益成長0%収益成長率1.4%将来の株主資本利益率8.94%アナリストカバレッジGood最終更新日28 May 2026今後の成長に関する最新情報お知らせ • Jul 24ICON Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company updates full-year financial guidance and now expect full-year revenue to be in the range of $7,850 million - $8,150 million, an increase of approximately 1% at the midpoint from prior full-year revenue guidance range.お知らせ • May 01Icon Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company Updated full-year 2025 financial revenue guidance in the range of $7,750 - $8,150 million, representing a year - over - year decrease of -6.4% to -1.6%.お知らせ • Feb 22ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025ICON Public Limited Company Reaffirmed earnings guidance for the year 2025. The company is re-affirming previously communicated full-year 2025 financial revenue guidance in the range of $8,050 million - $8,650 million.お知らせ • Jan 15ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025ICON Public Limited Company reaffirmed earning guidance for the full year 2024 and provided earning guidance for the full year 2025. For the full year 2024 the company reaffirms its current guidance of revenue in the range of $8,260million to $8,300 million. For the full year 2025, the company is expected revenue to be in the range of $8,050 million to $8,650 million, representing growth of approximately 1% at the midpoint.お知らせ • Oct 24ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024ICON Public Limited Company updated earnings guidance for the full year 2024. For the period, the company is updating full-year 2024 financial revenue guidance in the range of $8,260 million - $8,300 million, representing a year over year increase of 1.7% to 2.2%.お知らせ • Jul 25ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024ICON Public Limited Company updated earnings guidance for the full-year 2024. The company updating full-year 2024 financial revenue guidance in the range of $8,450 to $8,550 million, representing a year over year increase of 4.1% to 5.3%.すべての更新を表示Recent updatesお知らせ • May 27ICON Public Limited Company to Report Q4, 2025 Results on May 27, 2026ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on May 27, 2026お知らせ • May 03ICON Public Limited Company announced delayed 20-F filingOn 05/01/2026, ICON Public Limited Company announced that they will be unable to file their next 20-F by the deadline required by the SEC.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to Mex$1,850, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Life Sciences industry globally. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,096 per share.お知らせ • Mar 11An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC.An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025.お知らせ • Feb 12ICON Public Limited Company to Report Q4, 2025 Results on Apr 30, 2026ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2026お知らせ • Dec 09ICON plc Releases Findings from Two Biotech Sector SurveyICON plc released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East. ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&D priorities since its last survey in 2023. It positions China's presence as a positive signal for the global industry, with the findings highlighting how Western biotechs must adapt to maintain competitiveness and drive innovation. Funding remains a key challenge and 41% of organizations are actively seeking additional R&D funding, a 27% increase since 2023, highlighting ongoing financial pressures across the industry. Globally, the top three sources of funding are unchanged: large pharma partnerships, venture capital (VC), and government grants. However, the survey shows how VC funds have expanded their focus, with APAC biotechs stating VC funding was 60% of their current funding source versus 32% for US and 30% for Europe. This is leading some biotechs to explore innovative funding sources and ICON highlights the emerging models being increasingly adopted, including royalty financing, carve-outs, and crowdfunding. Since the last survey, access to talent is becoming more of a concern. This was more pronounced in APAC where responders were almost three times as likely to list talent shortages as having operational impact as their global counterparts (47% vs 18% in the US and 17% in Europe). The survey reveals leading next-generation modalities; notably, cell therapy has overtaken small molecules and is now most prominent, making up 40% of organizations' pipelines. Antibody drug conjugates (ADCs) and microbiome therapies are not far behind at 31%. Therapeutic focus areas have also evolved since the last survey findings, with neurology (44%), cardiovascular (39%), and immune disorders (32%) now outpacing a previous dominance in oncology. Despite the multiple macro challenges they face, the biggest risk to biotechs' operations is the complexity of drug development. Almost three quarters of respondents (73%) ranked this among their top five micro factorsposing the greatest risk to their organisation's operations. The survey highlighted how biotech companies are increasingly embracing digital technologies to improve operations, with 76% of respondents anticipating AI and other technologies will significantly accelerate R&D processes within the next two years. When asked which factors have the most potential to accelerate drug development, 41% of respondents selected AI-enabled asset selection in drug discovery, an increase from 26% in 2023. ION's separate survey of China-based biotechs, was based on 100 respondents. The findings highlighted that the challenges China-based biotechs face align with their global counterparts, most notably funding, and the complexity of drug development and regulations. Cardiovascular and oncology remain the top therapeutic focus areas in China, in contrast to the global shift toward neurology. However, cell therapy, microbiome therapies, and ADCs dominate pipelines across all regions. Respondents in China also report less concern about geopolitical developments and greater confidence in investment and product success.お知らせ • Dec 02Icon plc Announces Results of Its Latest Industry SurveyICON plc announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered perspectives from a wide range of clinical trial sites and is not limited to studies managed by ICON. It reveals widespread sentiment that sites are increasingly burdened by operational bottlenecks, contract and budget delays, and communication gaps. These challenges contribute to significant disruptions at the startup stage, with 55% of respondents reporting that time from site selection to full activation is longer than 5 months, and 39% reporting longer timelines than two years ago. Contract and budget delays are a persistent issue, with 66% of respondents experiencing them frequently. Almost all respondents (92%) identified these as the top areas where both sponsors and contract research organizations (CROs) can improve support. With 47% of respondents rating sponsor and CRO communication as average or poor, this highlights a critical need for site-centricity.お知らせ • Oct 23+ 1 more updateIcon plc Reports Goodwill Impairment for the Third Quarter Ended September 30, 2025ICON plc reported Goodwill impairment for the third quarter ended September 30, 2025. For the period, the company reported impairment of $165.3 million was recorded in respect of the Data Solutions Reporting Unit.Board Change • Sep 29Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 24ICON Public Limited Company to Report Q3, 2025 Results on Oct 22, 2025ICON Public Limited Company announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Sep 22ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD)ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD)Board Change • Sep 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 04+ 1 more updateICON plc Appoints Barry Balfe to the BoardICON plc announced that the board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to the Board. Balfe has deep knowledge of the CRO industry and has served as ICON’s Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the ICON executive leadership team in 2019 and served as President of Functional Services and then as President of Pharma Solutions.お知らせ • Jul 24ICON Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company updates full-year financial guidance and now expect full-year revenue to be in the range of $7,850 million - $8,150 million, an increase of approximately 1% at the midpoint from prior full-year revenue guidance range.お知らせ • Jun 23ICON Public Limited Company to Report Q2, 2025 Results on Jul 23, 2025ICON Public Limited Company announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Jun 12ICON Public Limited Company, Annual General Meeting, Jul 22, 2025ICON Public Limited Company, Annual General Meeting, Jul 22, 2025. Location: south county business park, leopardstown., dublin 18 Irelandお知らせ • May 01Icon Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company Updated full-year 2025 financial revenue guidance in the range of $7,750 - $8,150 million, representing a year - over - year decrease of -6.4% to -1.6%.お知らせ • Mar 31ICON Public Limited Company to Report Q1, 2025 Results on Apr 30, 2025ICON Public Limited Company announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2025お知らせ • Feb 22ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025ICON Public Limited Company Reaffirmed earnings guidance for the year 2025. The company is re-affirming previously communicated full-year 2025 financial revenue guidance in the range of $8,050 million - $8,650 million.お知らせ • Feb 20ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $750 million worth of its shares.ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its shares.お知らせ • Feb 12Robbins LLP Announces Class Action Lawsuit Against ICON PLCRobbins LLP informed stockholders that a class action was filed on behalf of all purchasers of ICON PLC ordinary shares between July 27, 2023 and October 23, 2024. The Allegations: Robbins LLP is Investigating Allegations that ICON PLC (ICLR) Misled Investors Regarding Demand. According to the complaint, during the class period, defendants failed to disclose that: (a) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company's client base; (b) ICON's purported FSP and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the RFPs ICON received from its biotechnology customers during the class period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d) ICON's customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e) ICON's two larger customers were diversifying their CRO providers away from the Company; (f) as a result of (a)-(e) above, ICON's reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON's services; and (g) that as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the class period and such guidance lacked a reasonable factual basis.お知らせ • Jan 30Icon Portfolio of Ai Tools Drives Clinical Trial EfficienciesICON plc announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting. ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI solutions that accelerate trials, enhance data and optimise operational efficiencies. The centre is supported by an AI Governance Committee, which oversees ethical, legal and data privacy standards in the deployment of new solutions. The latest solutions to be launched are: Submit, which automates the clinical trial document management process. It uses AI to improve compliance, reduce the burden on clinical project teams, and manage documents in an efficient and accurate way based on defined rules. Mapi Research Trust COA leverages AI to remain current with latest Clinical Outcome Assessments (COAs) from public sources in near real-time. It provides comprehensive intelligence to support optimal clinical trial protocols/designs. FORWARD+ is an AI-enabled capability that provides industry-leading visibility into resource demands, allocations and forecasting. FORWARD+ ensures efficient resource management through the clinical trial process. Study Start-up Site Contracts is an AI-enabled capability that streamlines the clinical contract drafting process by leveraging historical clinical contracts in order to create comprehensive near final draft contracts. OMR AI Navigation Assistant empowers operational clinical study metrics with generative AI to provide industry-leading analytics to transform data into business insights. Based on its success to date in implementing innovative AI solutions for its customers, ICON plans to further enhance its award-winning capabilities in how AI can drive productivity and efficiencies in clinical trials, with support from Enterprise Ireland. This sustained focus on investment in AI solutions by ICON will support its customers as they look to overcome some of the challenges in realising the potential of AI in drug development. A recent ICON survey of biopharma companies found that 13% of respondents indicated that while AI and digital technologies are being heavily used in single development programs, it is challenging for organizations to systemically incorporate them, possibly due to the complexity of managing such strategic, enterprise-scale digital disruption.お知らせ • Jan 29ICON Public Limited Company to Report Q4, 2024 Results on Feb 19, 2025ICON Public Limited Company announced that they will report Q4, 2024 results After-Market on Feb 19, 2025お知らせ • Jan 15ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025ICON Public Limited Company reaffirmed earning guidance for the full year 2024 and provided earning guidance for the full year 2025. For the full year 2024 the company reaffirms its current guidance of revenue in the range of $8,260million to $8,300 million. For the full year 2025, the company is expected revenue to be in the range of $8,050 million to $8,650 million, representing growth of approximately 1% at the midpoint.お知らせ • Jan 08Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative DisordersICON plc released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: 'Early, precise and efficient: The methods and technologies advancing Alzheimer's and Parkinson's R&D'. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation. The use of biomarkers can sometimes make a trial longer, more expensive, and slower to enrol patients. However, implementation of biomarker tests could be increasingly implemented to address some of the more resource-intensive eligibility criteria, such as imaging or CSF status. Innovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only 28% of respondents reported implementing an adaptive trial design of any type, while even fewer reported using historic controls (22%) or master protocol designs (19%), all of which can accelerate patient recruitment. Encouragingly, the survey revealed sponsors are not deterred from investing in R&D, especially in a diversified way. A large majority of respondents (87%) reported that they plan to invest in multiple therapeutic areas or a combination approach. They are also using AI to accelerate R&D, predominantly for the initial steps of the development process. For example, half of respondents who reported using AI or machine learning employ it for hypothesis generation (48%) and lead discovery (50%). Interestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only 29% of respondents indicated that it was an area that could support and accelerate R&D.お知らせ • Dec 18ICON plc Announces Appointment of Barry Balfe as Chief Operating OfficerICON plc announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to customers and further enhance the company's strategy to become the healthcare intelligence partner of choice in the industry. Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler.お知らせ • Oct 25ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares.ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of its shares.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$2.38 (vs US$1.99 in 3Q 2023)Third quarter 2024 results: EPS: US$2.38 (up from US$1.99 in 3Q 2023). Revenue: US$2.03b (down 1.2% from 3Q 2023). Net income: US$197.1m (up 20% from 3Q 2023). Profit margin: 9.7% (up from 8.0% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 24ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024ICON Public Limited Company updated earnings guidance for the full year 2024. For the period, the company is updating full-year 2024 financial revenue guidance in the range of $8,260 million - $8,300 million, representing a year over year increase of 1.7% to 2.2%.Board Change • Oct 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 27ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024ICON Public Limited Company announced that they will report Q3, 2024 results After-Market on Oct 23, 2024お知らせ • Aug 15ICON plc Announces Chief Financial Officer ChangesICON plc announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare’s CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes and oversaw strong financial growth across multiple business lines. Most recently, Nigel was CFO at LetsGetChecked, a global provider of at-home healthcare services. Nigel has a long tenure and a strong track record of success as CFO in a number of large organizations in the life sciences and healthcare services industry. He has successfully led and supported the financial growth of a number of organizations and has a strong background as a CFO of a public company with significant experience in M&A as well as financial processes and systems enhancement. Nigel holds a Bachelor of Science (Accounting) degree and a Master of Accounting degree from Queen’s University Belfast and is also a qualified chartered accountant and a fellow of Chartered Accountants Ireland. Nigel will be based in ICON’s Dublin office and will join ICON early in quarter four this year. The company tanks to its outgoing CFO, Brendan Brennan, for his significant contribution to ICON over the past 18 years.お知らせ • Jul 25ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024ICON Public Limited Company updated earnings guidance for the full-year 2024. The company updating full-year 2024 financial revenue guidance in the range of $8,450 to $8,550 million, representing a year over year increase of 4.1% to 5.3%.お知らせ • Jul 24ICON Public Limited Company Announces Board ChangesICON Public Limited Company confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director, at its AGM held on July 24, 2024. Ms. Whitaker is an experienced healthcare executive, advisor and director. She currently serves as managing partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, CEO and Chair of the Board of Aerami Therapeutics, and as an operating partner of NewVale Capital, a private equity firm. Ms. Whitaker was previously CEO and director of Novoclem Therapeutics. Earlier in her career, Ms. Whitaker held senior executive leadership positions at Bausch Health, Sanofi, GlaxoSmithKline, and multiple CEO roles for private and public development-stage companies. Ms. Whitaker serves as the Chair of QurAlis and as a non-executive director of Nykode Therapeutics, Trinity Life Sciences, Byrn Pharma and Bespak. She is a member of the Board of Trustees of the University of North Alabama. She previously served on the boards of Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Cree, Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group and Synta Pharmaceuticals. She holds a BSc in Chemistry and Business from the University of North Alabama.お知らせ • Jul 02ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024ICON Public Limited Company announced that they will report Q2, 2024 results After-Market on Jul 24, 2024お知らせ • Jun 13ICON Public Limited Company, Annual General Meeting, Jul 23, 2024ICON Public Limited Company, Annual General Meeting, Jul 23, 2024. Location: south county business park, leopardstown, dublin 18 Irelandお知らせ • May 31ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024ICON Public Limited Company reaffirmed earnings guidance for the year 2024. Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 million - $8,720 million, representing a year over year increase of 4.4% to 7.4%.Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$2.27 (vs US$1.43 in 1Q 2023)First quarter 2024 results: EPS: US$2.27 (up from US$1.43 in 1Q 2023). Revenue: US$2.09b (up 5.7% from 1Q 2023). Net income: US$187.4m (up 61% from 1Q 2023). Profit margin: 9.0% (up from 5.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Global Life Sciences industry.Board Change • Apr 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 04+ 1 more updateBrendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024ICON plc announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry. Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer. ICON has commenced a search to identify the next CFO.お知らせ • Mar 26ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024ICON Public Limited Company announced that they will report Q1, 2024 results After-Market on Apr 24, 2024お知らせ • Feb 22+ 1 more updateICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024ICON Public Limited Company reaffirmed Earnings Guidance for the Full Year 2024. For the year, the company expects revenue guidance in the range of $8,400 million - $8,800 million, representing a year over year increase of 3.4% to 8.4%.お知らせ • Jan 31ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024ICON Public Limited Company announced that they will report Q4, 2023 results After-Market on Feb 21, 2024Board Change • Jan 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 10ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024. For the period, the company expected revenue in the range of $8,070 million - $8,210 million and adjusted earnings per share1in the range of $12.63- $12.91.For the year, the company expects revenue guidance in the range of $8,400 million - $8,800 million, representing growth of 3.2% – 8.1% over Full Year 2023 Revenue guidance midpoint.Board Change • Nov 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 26+ 1 more updateICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions on October 2023.ICON Public Limited Company (NasdaqGS:ICLR) completed the acquisition of Philips Pharma Solutions on October 2023.Board Change • Sep 28Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 22ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023ICON Public Limited Company announced that they will report Q3, 2023 results After-Market on Oct 25, 2023お知らせ • Sep 21ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation SolutionICON plc announced the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON's proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON's next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to allow for the collation of patient data in a consented, discreet and non-intrusive way with Privacy Protected Record Linkage (PPRL) across time and source. Furthermore, ICON's capability to generate multiple tokens, coupled with advanced analytics, provides highly accurate matching (up to 90%) of clinical trial participants to the ecosystem of real-world data sources in the United States. This enables the best available secondary data to be used, resulting in enhanced evidence generation in a highly cost and time efficient manner for customers, with robust protection of patient privacy. Valuable insights from this offering can be leveraged in many ways, including regulatory and reimbursement discussions and scientific publications to optimise clinical development lifecycles. This can also be used to better understand the response of specific sub-cohorts of patients, and to conduct long-term safety surveillance. ICON's Clinical Trial Tokenisation solution is delivered within an operating framework aligned to industry security and data privacy standards, and its corporate security and data protection programs have been assessed to ISO 27001 and 27701 standards. ICON is uniquely positioned to support customers because, in addition to commercialisation capability, it has extensive experience in clinical research, regulatory management, and healthcare intelligence, all crucial to clinical trial tokenisation.お知らせ • Sep 14ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical TrialICON plc announced that it is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates. Next generation COVID-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of the virus, extend the duration of protection, and offer better protection in the prevention of illness and transmission over the current state of vaccine technologies. Against this backdrop, the Government & Public Health Solutions team at ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infection. The trial will involve 10,000 subjects, expected to be enrolled over a six-month period. BARDA will select the vaccine candidate to be investigated in this trial, thereby accelerating the start of the Phase 2b clinical trial to support in benchmarking its efficacy against existing vaccines. ICON has extensive experience in vaccine clinical development for commercial businesses, governments and NGOs, having participated in over 184 vaccine studies in the past five years. This experience has already helped ICON play a significant role in the search for vaccines and treatments for COVID-19. The company has partnered with its customers on the development of a number of approved vaccines. ICON has conducted or is currently involved in over 86 COVID-19 related trials. In addition to its Government & Public Health Solutions team, ICON draws on the expertise of its biotech division, which comprises over 8,000 staff dedicated to biotech customers. As the world’s largest dedicated biotech division, the team works with over 500 biotech sponsors annually. This trial is part of Project NextGen, which coordinates across the U.S. Government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability. BARDA is responsible for developing medical countermeasures to secure the U.S. against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. Since 2014, ICON has been a member of BARDA’s Medical Countermeasures Clinical Studies Network (CSN). The network supports planning and implementation of clinical studies for medical countermeasure development. ICON has worked on numerous clinical trials as part of this network, including, most recently, the execution of an anthrax vaccine clinical trial. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50120D00017.お知らせ • Jun 28ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023ICON Public Limited Company announced that they will report Q2, 2023 results After-Market on Jul 26, 2023お知らせ • Jun 13ICON Public Limited Company, Annual General Meeting, Jul 25, 2023ICON Public Limited Company, Annual General Meeting, Jul 25, 2023, at 08:30 Coordinated Universal Time. Location: ICON's global headquarters in South County Business Park, Leopardstown Dublin 18 Ireland Agenda: To consider reelection of directors; to review the Company's affairs and consider ICON's 2022 accounts which have been audited by KPMG, ICON's independent auditors; to authorize the Directors to fix the remuneration of the auditors; to consider authority to issue shares up to 20% of share capital; to consider authority to issue shares up to 20% of share capital without offering to existing shareholders; to consider authority to buy back shares up to 10% of share capital; to transact other business.Reported Earnings • Apr 29First quarter 2023 earnings released: EPS: US$1.43 (vs US$1.37 in 1Q 2022)First quarter 2023 results: EPS: US$1.43 (up from US$1.37 in 1Q 2022). Revenue: US$1.98b (up 4.0% from 1Q 2022). Net income: US$116.7m (up 4.2% from 1Q 2022). Profit margin: 5.9% (in line with 1Q 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Global Life Sciences industry.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to Mex$3,703, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 33x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,833 per share.Board Change • Apr 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 24Full year 2022 earnings released: EPS: US$6.20 (vs US$2.28 in FY 2021)Full year 2022 results: EPS: US$6.20 (up from US$2.28 in FY 2021). Revenue: US$7.74b (up 41% from FY 2021). Net income: US$505.3m (up 230% from FY 2021). Profit margin: 6.5% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Global Life Sciences industry.お知らせ • Jan 27ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023ICON Public Limited Company announced that they will report Q4, 2022 results After-Market on Feb 22, 2023お知らせ • Jan 11Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023ICON Public Limited Company reaffirmed revenue guidance for full year 2022 and provided revenue guidance for full year 2023. For full year 2022, the company reaffirmed its current guidance of revenue in the range of $7,690 - $7,810 million. For the full year 2023, revenue is expected to be in the range of $7,940 - $8,340 million, representing growth of 3.3% – 6.8%, and adjusted earnings per share1 is expected to be in the range of $12.40 – $13.05, representing growth of 6.4% – 10.1%, over Full Year 2022 revenue.Board Change • Jan 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03Third quarter 2022 earnings released: EPS: US$1.96 (vs US$1.17 loss in 3Q 2021)Third quarter 2022 results: EPS: US$1.96 (up from US$1.17 loss in 3Q 2021). Revenue: US$1.94b (up 4.1% from 3Q 2021). Net income: US$160.2m (up US$254.4m from 3Q 2021). Profit margin: 8.2% (up from net loss in 3Q 2021). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Global Life Sciences industry.Reported Earnings • Jul 28Second quarter 2022 earnings released: EPS: US$1.42 (vs US$1.40 in 2Q 2021)Second quarter 2022 results: EPS: US$1.42 (up from US$1.40 in 2Q 2021). Revenue: US$1.94b (up 122% from 2Q 2021). Net income: US$115.7m (up 57% from 2Q 2021). Profit margin: 6.0% (down from 8.5% in 2Q 2021). Over the next year, revenue is forecast to grow 7.3%, compared to a 12% growth forecast for the industry in Mexico.業績と収益の成長予測BMV:ICLR N - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20288,3866399731,077712/31/20278,0635708811,0011412/31/20267,8545136869511412/31/20258,2512298621,036N/A9/30/20258,1035999641,140N/A6/30/20258,0907949901,155N/A3/31/20258,1937581,0581,228N/A12/31/20248,2827911,1191,287N/A9/30/20248,3077481,2291,388N/A6/30/20248,3327141,1821,327N/A3/31/20248,2326831,1721,313N/A12/31/20238,1206121,0201,161N/A9/30/20238,016513516661N/A6/30/20237,903510381534N/A3/31/20237,818510363512N/A12/31/20227,741505421563N/A9/30/20227,665464780913N/A6/30/20227,588210878998N/A3/31/20226,524168839944N/A12/31/20215,481153735829N/A9/30/20214,356178676735N/A6/30/20213,191364506548N/A3/31/20212,940338499537N/A12/31/20202,797328527568N/A9/30/20202,762322460507N/A6/30/20202,771324502556N/A3/31/20202,846368406461N/A12/31/20192,806369374413N/A9/30/20192,759362N/A339N/A6/30/20192,704353N/A306N/A3/31/20192,651333N/A323N/A12/31/20182,596323N/A269N/A9/30/20182,372306N/A314N/A6/30/20182,157295N/A294N/A3/31/20181,947288N/A264N/A12/31/20171,758281N/A383N/A9/30/20171,738285N/A407N/A6/30/20171,718274N/A350N/A3/31/20171,698271N/A359N/A12/31/20161,666262N/A259N/A9/30/20161,635251N/A245N/A6/30/20161,609249N/A267N/A3/31/20161,587247N/A277N/A12/31/20151,575240N/A279N/A9/30/20151,562221N/A239N/A6/30/20151,555210N/A275N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ICLR Nの予測収益成長率 (年間15.5% ) は 貯蓄率 ( 9% ) を上回っています。収益対市場: ICLR Nの収益 ( 15.5% ) はMX市場 ( 8.5% ) よりも速いペースで成長すると予測されています。高成長収益: ICLR Nの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: ICLR Nの収益 ( 1.4% ) MX市場 ( 6.2% ) よりも低い成長が予測されています。高い収益成長: ICLR Nの収益 ( 1.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ICLR Nの 自己資本利益率 は、3年後には低くなると予測されています ( 8.9 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 19:55終値2026/03/27 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ICON Public Limited Company 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関Eric ColdwellBairdDouglas TsaoBarclaysLuke SergottBarclays27 その他のアナリストを表示
お知らせ • Jul 24ICON Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company updates full-year financial guidance and now expect full-year revenue to be in the range of $7,850 million - $8,150 million, an increase of approximately 1% at the midpoint from prior full-year revenue guidance range.
お知らせ • May 01Icon Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company Updated full-year 2025 financial revenue guidance in the range of $7,750 - $8,150 million, representing a year - over - year decrease of -6.4% to -1.6%.
お知らせ • Feb 22ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025ICON Public Limited Company Reaffirmed earnings guidance for the year 2025. The company is re-affirming previously communicated full-year 2025 financial revenue guidance in the range of $8,050 million - $8,650 million.
お知らせ • Jan 15ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025ICON Public Limited Company reaffirmed earning guidance for the full year 2024 and provided earning guidance for the full year 2025. For the full year 2024 the company reaffirms its current guidance of revenue in the range of $8,260million to $8,300 million. For the full year 2025, the company is expected revenue to be in the range of $8,050 million to $8,650 million, representing growth of approximately 1% at the midpoint.
お知らせ • Oct 24ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024ICON Public Limited Company updated earnings guidance for the full year 2024. For the period, the company is updating full-year 2024 financial revenue guidance in the range of $8,260 million - $8,300 million, representing a year over year increase of 1.7% to 2.2%.
お知らせ • Jul 25ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024ICON Public Limited Company updated earnings guidance for the full-year 2024. The company updating full-year 2024 financial revenue guidance in the range of $8,450 to $8,550 million, representing a year over year increase of 4.1% to 5.3%.
お知らせ • May 27ICON Public Limited Company to Report Q4, 2025 Results on May 27, 2026ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on May 27, 2026
お知らせ • May 03ICON Public Limited Company announced delayed 20-F filingOn 05/01/2026, ICON Public Limited Company announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to Mex$1,850, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Life Sciences industry globally. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,096 per share.
お知らせ • Mar 11An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC.An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025.
お知らせ • Feb 12ICON Public Limited Company to Report Q4, 2025 Results on Apr 30, 2026ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2026
お知らせ • Dec 09ICON plc Releases Findings from Two Biotech Sector SurveyICON plc released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East. ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&D priorities since its last survey in 2023. It positions China's presence as a positive signal for the global industry, with the findings highlighting how Western biotechs must adapt to maintain competitiveness and drive innovation. Funding remains a key challenge and 41% of organizations are actively seeking additional R&D funding, a 27% increase since 2023, highlighting ongoing financial pressures across the industry. Globally, the top three sources of funding are unchanged: large pharma partnerships, venture capital (VC), and government grants. However, the survey shows how VC funds have expanded their focus, with APAC biotechs stating VC funding was 60% of their current funding source versus 32% for US and 30% for Europe. This is leading some biotechs to explore innovative funding sources and ICON highlights the emerging models being increasingly adopted, including royalty financing, carve-outs, and crowdfunding. Since the last survey, access to talent is becoming more of a concern. This was more pronounced in APAC where responders were almost three times as likely to list talent shortages as having operational impact as their global counterparts (47% vs 18% in the US and 17% in Europe). The survey reveals leading next-generation modalities; notably, cell therapy has overtaken small molecules and is now most prominent, making up 40% of organizations' pipelines. Antibody drug conjugates (ADCs) and microbiome therapies are not far behind at 31%. Therapeutic focus areas have also evolved since the last survey findings, with neurology (44%), cardiovascular (39%), and immune disorders (32%) now outpacing a previous dominance in oncology. Despite the multiple macro challenges they face, the biggest risk to biotechs' operations is the complexity of drug development. Almost three quarters of respondents (73%) ranked this among their top five micro factorsposing the greatest risk to their organisation's operations. The survey highlighted how biotech companies are increasingly embracing digital technologies to improve operations, with 76% of respondents anticipating AI and other technologies will significantly accelerate R&D processes within the next two years. When asked which factors have the most potential to accelerate drug development, 41% of respondents selected AI-enabled asset selection in drug discovery, an increase from 26% in 2023. ION's separate survey of China-based biotechs, was based on 100 respondents. The findings highlighted that the challenges China-based biotechs face align with their global counterparts, most notably funding, and the complexity of drug development and regulations. Cardiovascular and oncology remain the top therapeutic focus areas in China, in contrast to the global shift toward neurology. However, cell therapy, microbiome therapies, and ADCs dominate pipelines across all regions. Respondents in China also report less concern about geopolitical developments and greater confidence in investment and product success.
お知らせ • Dec 02Icon plc Announces Results of Its Latest Industry SurveyICON plc announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered perspectives from a wide range of clinical trial sites and is not limited to studies managed by ICON. It reveals widespread sentiment that sites are increasingly burdened by operational bottlenecks, contract and budget delays, and communication gaps. These challenges contribute to significant disruptions at the startup stage, with 55% of respondents reporting that time from site selection to full activation is longer than 5 months, and 39% reporting longer timelines than two years ago. Contract and budget delays are a persistent issue, with 66% of respondents experiencing them frequently. Almost all respondents (92%) identified these as the top areas where both sponsors and contract research organizations (CROs) can improve support. With 47% of respondents rating sponsor and CRO communication as average or poor, this highlights a critical need for site-centricity.
お知らせ • Oct 23+ 1 more updateIcon plc Reports Goodwill Impairment for the Third Quarter Ended September 30, 2025ICON plc reported Goodwill impairment for the third quarter ended September 30, 2025. For the period, the company reported impairment of $165.3 million was recorded in respect of the Data Solutions Reporting Unit.
Board Change • Sep 29Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 24ICON Public Limited Company to Report Q3, 2025 Results on Oct 22, 2025ICON Public Limited Company announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Sep 22ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD)ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD)
Board Change • Sep 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 04+ 1 more updateICON plc Appoints Barry Balfe to the BoardICON plc announced that the board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to the Board. Balfe has deep knowledge of the CRO industry and has served as ICON’s Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the ICON executive leadership team in 2019 and served as President of Functional Services and then as President of Pharma Solutions.
お知らせ • Jul 24ICON Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company updates full-year financial guidance and now expect full-year revenue to be in the range of $7,850 million - $8,150 million, an increase of approximately 1% at the midpoint from prior full-year revenue guidance range.
お知らせ • Jun 23ICON Public Limited Company to Report Q2, 2025 Results on Jul 23, 2025ICON Public Limited Company announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Jun 12ICON Public Limited Company, Annual General Meeting, Jul 22, 2025ICON Public Limited Company, Annual General Meeting, Jul 22, 2025. Location: south county business park, leopardstown., dublin 18 Ireland
お知らせ • May 01Icon Public Limited Company Updates Earnings Guidance for Full Year 2025ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company Updated full-year 2025 financial revenue guidance in the range of $7,750 - $8,150 million, representing a year - over - year decrease of -6.4% to -1.6%.
お知らせ • Mar 31ICON Public Limited Company to Report Q1, 2025 Results on Apr 30, 2025ICON Public Limited Company announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2025
お知らせ • Feb 22ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025ICON Public Limited Company Reaffirmed earnings guidance for the year 2025. The company is re-affirming previously communicated full-year 2025 financial revenue guidance in the range of $8,050 million - $8,650 million.
お知らせ • Feb 20ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $750 million worth of its shares.ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its shares.
お知らせ • Feb 12Robbins LLP Announces Class Action Lawsuit Against ICON PLCRobbins LLP informed stockholders that a class action was filed on behalf of all purchasers of ICON PLC ordinary shares between July 27, 2023 and October 23, 2024. The Allegations: Robbins LLP is Investigating Allegations that ICON PLC (ICLR) Misled Investors Regarding Demand. According to the complaint, during the class period, defendants failed to disclose that: (a) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company's client base; (b) ICON's purported FSP and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the RFPs ICON received from its biotechnology customers during the class period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d) ICON's customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e) ICON's two larger customers were diversifying their CRO providers away from the Company; (f) as a result of (a)-(e) above, ICON's reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON's services; and (g) that as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the class period and such guidance lacked a reasonable factual basis.
お知らせ • Jan 30Icon Portfolio of Ai Tools Drives Clinical Trial EfficienciesICON plc announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting. ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI solutions that accelerate trials, enhance data and optimise operational efficiencies. The centre is supported by an AI Governance Committee, which oversees ethical, legal and data privacy standards in the deployment of new solutions. The latest solutions to be launched are: Submit, which automates the clinical trial document management process. It uses AI to improve compliance, reduce the burden on clinical project teams, and manage documents in an efficient and accurate way based on defined rules. Mapi Research Trust COA leverages AI to remain current with latest Clinical Outcome Assessments (COAs) from public sources in near real-time. It provides comprehensive intelligence to support optimal clinical trial protocols/designs. FORWARD+ is an AI-enabled capability that provides industry-leading visibility into resource demands, allocations and forecasting. FORWARD+ ensures efficient resource management through the clinical trial process. Study Start-up Site Contracts is an AI-enabled capability that streamlines the clinical contract drafting process by leveraging historical clinical contracts in order to create comprehensive near final draft contracts. OMR AI Navigation Assistant empowers operational clinical study metrics with generative AI to provide industry-leading analytics to transform data into business insights. Based on its success to date in implementing innovative AI solutions for its customers, ICON plans to further enhance its award-winning capabilities in how AI can drive productivity and efficiencies in clinical trials, with support from Enterprise Ireland. This sustained focus on investment in AI solutions by ICON will support its customers as they look to overcome some of the challenges in realising the potential of AI in drug development. A recent ICON survey of biopharma companies found that 13% of respondents indicated that while AI and digital technologies are being heavily used in single development programs, it is challenging for organizations to systemically incorporate them, possibly due to the complexity of managing such strategic, enterprise-scale digital disruption.
お知らせ • Jan 29ICON Public Limited Company to Report Q4, 2024 Results on Feb 19, 2025ICON Public Limited Company announced that they will report Q4, 2024 results After-Market on Feb 19, 2025
お知らせ • Jan 15ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025ICON Public Limited Company reaffirmed earning guidance for the full year 2024 and provided earning guidance for the full year 2025. For the full year 2024 the company reaffirms its current guidance of revenue in the range of $8,260million to $8,300 million. For the full year 2025, the company is expected revenue to be in the range of $8,050 million to $8,650 million, representing growth of approximately 1% at the midpoint.
お知らせ • Jan 08Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative DisordersICON plc released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: 'Early, precise and efficient: The methods and technologies advancing Alzheimer's and Parkinson's R&D'. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation. The use of biomarkers can sometimes make a trial longer, more expensive, and slower to enrol patients. However, implementation of biomarker tests could be increasingly implemented to address some of the more resource-intensive eligibility criteria, such as imaging or CSF status. Innovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only 28% of respondents reported implementing an adaptive trial design of any type, while even fewer reported using historic controls (22%) or master protocol designs (19%), all of which can accelerate patient recruitment. Encouragingly, the survey revealed sponsors are not deterred from investing in R&D, especially in a diversified way. A large majority of respondents (87%) reported that they plan to invest in multiple therapeutic areas or a combination approach. They are also using AI to accelerate R&D, predominantly for the initial steps of the development process. For example, half of respondents who reported using AI or machine learning employ it for hypothesis generation (48%) and lead discovery (50%). Interestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only 29% of respondents indicated that it was an area that could support and accelerate R&D.
お知らせ • Dec 18ICON plc Announces Appointment of Barry Balfe as Chief Operating OfficerICON plc announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to customers and further enhance the company's strategy to become the healthcare intelligence partner of choice in the industry. Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler.
お知らせ • Oct 25ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares.ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of its shares.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$2.38 (vs US$1.99 in 3Q 2023)Third quarter 2024 results: EPS: US$2.38 (up from US$1.99 in 3Q 2023). Revenue: US$2.03b (down 1.2% from 3Q 2023). Net income: US$197.1m (up 20% from 3Q 2023). Profit margin: 9.7% (up from 8.0% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 24ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024ICON Public Limited Company updated earnings guidance for the full year 2024. For the period, the company is updating full-year 2024 financial revenue guidance in the range of $8,260 million - $8,300 million, representing a year over year increase of 1.7% to 2.2%.
Board Change • Oct 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 27ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024ICON Public Limited Company announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
お知らせ • Aug 15ICON plc Announces Chief Financial Officer ChangesICON plc announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare’s CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes and oversaw strong financial growth across multiple business lines. Most recently, Nigel was CFO at LetsGetChecked, a global provider of at-home healthcare services. Nigel has a long tenure and a strong track record of success as CFO in a number of large organizations in the life sciences and healthcare services industry. He has successfully led and supported the financial growth of a number of organizations and has a strong background as a CFO of a public company with significant experience in M&A as well as financial processes and systems enhancement. Nigel holds a Bachelor of Science (Accounting) degree and a Master of Accounting degree from Queen’s University Belfast and is also a qualified chartered accountant and a fellow of Chartered Accountants Ireland. Nigel will be based in ICON’s Dublin office and will join ICON early in quarter four this year. The company tanks to its outgoing CFO, Brendan Brennan, for his significant contribution to ICON over the past 18 years.
お知らせ • Jul 25ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024ICON Public Limited Company updated earnings guidance for the full-year 2024. The company updating full-year 2024 financial revenue guidance in the range of $8,450 to $8,550 million, representing a year over year increase of 4.1% to 5.3%.
お知らせ • Jul 24ICON Public Limited Company Announces Board ChangesICON Public Limited Company confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director, at its AGM held on July 24, 2024. Ms. Whitaker is an experienced healthcare executive, advisor and director. She currently serves as managing partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, CEO and Chair of the Board of Aerami Therapeutics, and as an operating partner of NewVale Capital, a private equity firm. Ms. Whitaker was previously CEO and director of Novoclem Therapeutics. Earlier in her career, Ms. Whitaker held senior executive leadership positions at Bausch Health, Sanofi, GlaxoSmithKline, and multiple CEO roles for private and public development-stage companies. Ms. Whitaker serves as the Chair of QurAlis and as a non-executive director of Nykode Therapeutics, Trinity Life Sciences, Byrn Pharma and Bespak. She is a member of the Board of Trustees of the University of North Alabama. She previously served on the boards of Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Cree, Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group and Synta Pharmaceuticals. She holds a BSc in Chemistry and Business from the University of North Alabama.
お知らせ • Jul 02ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024ICON Public Limited Company announced that they will report Q2, 2024 results After-Market on Jul 24, 2024
お知らせ • Jun 13ICON Public Limited Company, Annual General Meeting, Jul 23, 2024ICON Public Limited Company, Annual General Meeting, Jul 23, 2024. Location: south county business park, leopardstown, dublin 18 Ireland
お知らせ • May 31ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024ICON Public Limited Company reaffirmed earnings guidance for the year 2024. Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 million - $8,720 million, representing a year over year increase of 4.4% to 7.4%.
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$2.27 (vs US$1.43 in 1Q 2023)First quarter 2024 results: EPS: US$2.27 (up from US$1.43 in 1Q 2023). Revenue: US$2.09b (up 5.7% from 1Q 2023). Net income: US$187.4m (up 61% from 1Q 2023). Profit margin: 9.0% (up from 5.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Global Life Sciences industry.
Board Change • Apr 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 04+ 1 more updateBrendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024ICON plc announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry. Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer. ICON has commenced a search to identify the next CFO.
お知らせ • Mar 26ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024ICON Public Limited Company announced that they will report Q1, 2024 results After-Market on Apr 24, 2024
お知らせ • Feb 22+ 1 more updateICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024ICON Public Limited Company reaffirmed Earnings Guidance for the Full Year 2024. For the year, the company expects revenue guidance in the range of $8,400 million - $8,800 million, representing a year over year increase of 3.4% to 8.4%.
お知らせ • Jan 31ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024ICON Public Limited Company announced that they will report Q4, 2023 results After-Market on Feb 21, 2024
Board Change • Jan 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 10ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024. For the period, the company expected revenue in the range of $8,070 million - $8,210 million and adjusted earnings per share1in the range of $12.63- $12.91.For the year, the company expects revenue guidance in the range of $8,400 million - $8,800 million, representing growth of 3.2% – 8.1% over Full Year 2023 Revenue guidance midpoint.
Board Change • Nov 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 26+ 1 more updateICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions on October 2023.ICON Public Limited Company (NasdaqGS:ICLR) completed the acquisition of Philips Pharma Solutions on October 2023.
Board Change • Sep 28Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 22ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023ICON Public Limited Company announced that they will report Q3, 2023 results After-Market on Oct 25, 2023
お知らせ • Sep 21ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation SolutionICON plc announced the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON's proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON's next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to allow for the collation of patient data in a consented, discreet and non-intrusive way with Privacy Protected Record Linkage (PPRL) across time and source. Furthermore, ICON's capability to generate multiple tokens, coupled with advanced analytics, provides highly accurate matching (up to 90%) of clinical trial participants to the ecosystem of real-world data sources in the United States. This enables the best available secondary data to be used, resulting in enhanced evidence generation in a highly cost and time efficient manner for customers, with robust protection of patient privacy. Valuable insights from this offering can be leveraged in many ways, including regulatory and reimbursement discussions and scientific publications to optimise clinical development lifecycles. This can also be used to better understand the response of specific sub-cohorts of patients, and to conduct long-term safety surveillance. ICON's Clinical Trial Tokenisation solution is delivered within an operating framework aligned to industry security and data privacy standards, and its corporate security and data protection programs have been assessed to ISO 27001 and 27701 standards. ICON is uniquely positioned to support customers because, in addition to commercialisation capability, it has extensive experience in clinical research, regulatory management, and healthcare intelligence, all crucial to clinical trial tokenisation.
お知らせ • Sep 14ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical TrialICON plc announced that it is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates. Next generation COVID-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of the virus, extend the duration of protection, and offer better protection in the prevention of illness and transmission over the current state of vaccine technologies. Against this backdrop, the Government & Public Health Solutions team at ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infection. The trial will involve 10,000 subjects, expected to be enrolled over a six-month period. BARDA will select the vaccine candidate to be investigated in this trial, thereby accelerating the start of the Phase 2b clinical trial to support in benchmarking its efficacy against existing vaccines. ICON has extensive experience in vaccine clinical development for commercial businesses, governments and NGOs, having participated in over 184 vaccine studies in the past five years. This experience has already helped ICON play a significant role in the search for vaccines and treatments for COVID-19. The company has partnered with its customers on the development of a number of approved vaccines. ICON has conducted or is currently involved in over 86 COVID-19 related trials. In addition to its Government & Public Health Solutions team, ICON draws on the expertise of its biotech division, which comprises over 8,000 staff dedicated to biotech customers. As the world’s largest dedicated biotech division, the team works with over 500 biotech sponsors annually. This trial is part of Project NextGen, which coordinates across the U.S. Government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability. BARDA is responsible for developing medical countermeasures to secure the U.S. against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. Since 2014, ICON has been a member of BARDA’s Medical Countermeasures Clinical Studies Network (CSN). The network supports planning and implementation of clinical studies for medical countermeasure development. ICON has worked on numerous clinical trials as part of this network, including, most recently, the execution of an anthrax vaccine clinical trial. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50120D00017.
お知らせ • Jun 28ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023ICON Public Limited Company announced that they will report Q2, 2023 results After-Market on Jul 26, 2023
お知らせ • Jun 13ICON Public Limited Company, Annual General Meeting, Jul 25, 2023ICON Public Limited Company, Annual General Meeting, Jul 25, 2023, at 08:30 Coordinated Universal Time. Location: ICON's global headquarters in South County Business Park, Leopardstown Dublin 18 Ireland Agenda: To consider reelection of directors; to review the Company's affairs and consider ICON's 2022 accounts which have been audited by KPMG, ICON's independent auditors; to authorize the Directors to fix the remuneration of the auditors; to consider authority to issue shares up to 20% of share capital; to consider authority to issue shares up to 20% of share capital without offering to existing shareholders; to consider authority to buy back shares up to 10% of share capital; to transact other business.
Reported Earnings • Apr 29First quarter 2023 earnings released: EPS: US$1.43 (vs US$1.37 in 1Q 2022)First quarter 2023 results: EPS: US$1.43 (up from US$1.37 in 1Q 2022). Revenue: US$1.98b (up 4.0% from 1Q 2022). Net income: US$116.7m (up 4.2% from 1Q 2022). Profit margin: 5.9% (in line with 1Q 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Global Life Sciences industry.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to Mex$3,703, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 33x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,833 per share.
Board Change • Apr 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 24Full year 2022 earnings released: EPS: US$6.20 (vs US$2.28 in FY 2021)Full year 2022 results: EPS: US$6.20 (up from US$2.28 in FY 2021). Revenue: US$7.74b (up 41% from FY 2021). Net income: US$505.3m (up 230% from FY 2021). Profit margin: 6.5% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Global Life Sciences industry.
お知らせ • Jan 27ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023ICON Public Limited Company announced that they will report Q4, 2022 results After-Market on Feb 22, 2023
お知らせ • Jan 11Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023ICON Public Limited Company reaffirmed revenue guidance for full year 2022 and provided revenue guidance for full year 2023. For full year 2022, the company reaffirmed its current guidance of revenue in the range of $7,690 - $7,810 million. For the full year 2023, revenue is expected to be in the range of $7,940 - $8,340 million, representing growth of 3.3% – 6.8%, and adjusted earnings per share1 is expected to be in the range of $12.40 – $13.05, representing growth of 6.4% – 10.1%, over Full Year 2022 revenue.
Board Change • Jan 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03Third quarter 2022 earnings released: EPS: US$1.96 (vs US$1.17 loss in 3Q 2021)Third quarter 2022 results: EPS: US$1.96 (up from US$1.17 loss in 3Q 2021). Revenue: US$1.94b (up 4.1% from 3Q 2021). Net income: US$160.2m (up US$254.4m from 3Q 2021). Profit margin: 8.2% (up from net loss in 3Q 2021). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Global Life Sciences industry.
Reported Earnings • Jul 28Second quarter 2022 earnings released: EPS: US$1.42 (vs US$1.40 in 2Q 2021)Second quarter 2022 results: EPS: US$1.42 (up from US$1.40 in 2Q 2021). Revenue: US$1.94b (up 122% from 2Q 2021). Net income: US$115.7m (up 57% from 2Q 2021). Profit margin: 6.0% (down from 8.5% in 2Q 2021). Over the next year, revenue is forecast to grow 7.3%, compared to a 12% growth forecast for the industry in Mexico.